Differences between radiology and histopathology: Are we judging correctly? Simona Onali 1, Emmanuel Tsochatzis 1, James O’Beirne 1, Aileen Marshall 1,

Slides:



Advertisements
Similar presentations
Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Advertisements

EC916 Eva Gallardo, MD Medical Manager, Biocompatibles UK Drug Eluting Bead: Clinical Updates and Histological Data.
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
High Intensity Focused Ultrasound (HIFU) for Liver Tumour Dr Dai Wing Chiu Queen Mary Hospital.
SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
Hepatocellular Carcinoma and Liver Transplantation TTS Key Opinion Leaders Meeting Montreal, April 2007 Mazen Hassanain MBBS, FRCS(C) Assistant Professor.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy R. Rossini, G. Musumeci,
L IVER TRANSPLANT IN HEPATOCELLULAR CARCINOMA. O UTLINE Indications Milan Criteria Expanded Milan Criteria (UCSF) Upto 7 Criteria MELD Scoring and T staging.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Andreas A. Rostved, MD Research assistant Department of Surgical Gastroenterology and Transplantation Rigshospitalet – Copenhagen University Hospital Denmark.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Incidence and prognosis of hepatocellular adenoma in Denmark Lars Bossen Departments of Hepatology and Gastroenterology and Clinical Epidemiology Aarhus.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
A2ALL When Using A2ALL Slides We welcome the use of A2ALL slides, as we value the distribution of our research for the benefit of patient care and transplant.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Treatment Strategy for Recurrent Hepatocellular Carcinoma: Salvage Transplantation, Repeated Resection, or Radiofrequency Ablation? Albert C. Y. Chan,
Management of Hepatocellular carcinoma
Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol Feb. R2 이 홍 주.
소화기내과 김경엽 Gastroenterology 2011;140:
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Dr. Mohammed Omar Khalifa
Prognostic significance of tumor subtypes in male breast cancer:
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
Prognosis of younger patients in non-small cell lung cancer
Clinical outcome after SVR: Veterans Affairs
39 DEVELOPED HCC by EASL criteria
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Outline.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Dr T P E Wells 13 July 2018 Breast SSG Bath
A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant.
Changes to HCC Criteria for Auto Approval
Predicting nodal metastasis among oral cancer patients
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Does Liver Regeneration Increase the Postoperative HCC Recurrence after Curative Resection ? Jin-Ho Lee, MD. Department of Surgery, Yonsei University.
KAHBPS , Gyeongju, Korea Long-term outcome after resection of huge hepatocellular carcinoma ≥10 cm: Single-institution experience with 471 patients:
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.
Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.
Presentation transcript:

Differences between radiology and histopathology: Are we judging correctly? Simona Onali 1, Emmanuel Tsochatzis 1, James O’Beirne 1, Aileen Marshall 1, TuVihn Luong 2, Massimo Pinzani 1, Pinelopi Manousou 1 1 The Royal Free Sheila Sherlock Liver Unit, Royal Free Hospital and UCL Institute for Liver and Digestive Health, London, UK 2 Department of Cellular Pathology, UCL Medical School, Royal Free Campus, London, UK

Background Selection criteria for OLT in patients with HCC are based on radiological assessment of the number and size of tumours  Retrospective studies about HCC patients undergoing LT reported different grade of discordance between radiological and histological findings 1-4. Factors other than tumour size and number may affect post-LT outcomes :  Pre-transplant aFP level >1000 ng/ml associated with higher risk of HCC recurrence even among patients transplanted within Milan criteria 5 1 Sotiropoulos 2005 Transplantation 2 Grasso 2006 Transplantation 3 Shah 2006 Transplantation 4 Chen 2009 HPB 5 Hameed 2014 Liver transplantation

Background Factors other than tumour size and number may affect post-LT outcomes : Pre-transplant aFP level >1000 ng/ml associated with higher risk of HCC recurrence even among patients transplanted within Milan criteria 1 strongest pre-transplant predictor of microvascular invasion New selection criteria based on the combination of size/number of HCC and aFP level have been proposed the French model (aFP model) 2 1Duvoux 2012 Gastroenterology

Aims of the study 1.To analyse any discrepancies between radiological reports and histopathological findings in the explant of patients undergoing LT for HCC 2.To identify potential factors that could predict HCC recurrence and survival post-LT between the parameters available during the pre-operative assessment period.

Patients and Methods All consecutive patients who underwent LT for HCC between January 1997 and February 2014 at the Royal Free Hospital Retrospectively: -Demographic and clinical data (sex, age, aetiology of liver disease, date of LT, pre-LT HCC treatment, aFP levels) -Pre-LT radiological findings (HCC number and size, macrovascular invasion, lymph-nodes invasion) -Histopathological findings on explant (HCC number and size, differentiation, micro/macrovascular invasion) -Donor characteristics -Immunosuppression type and levels -HCC recurrence and HCC-related death

Patients and Methods Discrepancy between radiological and histopathological findings was assessed comparing:  number of nodules  size of biggest nodule  fulfilment of Milan/UCSF criteria Patients were considered underestimated if: -nodule number and/or size was bigger on explant compared to imaging -they did not fulfil selection criteria on explant (in discordance to radiology) They were considered overestimated when the opposite occurred.

Results: baseline patients’ characheristics (n=185) Age median, range55 (27-68) Gender male150 (81%) Aetiology -HCV -HBV -ALD -Autoimmune -NAFLD -Other 101 (54%) 35 (19%) 28 (15%) 9 (5%) 7 (4%) 5 (3%) LT period (25%) 38 (20%) 59 (32%) 42 (23%) Pre-LT HCC treatment -Total -TAE/TACE -RFA -Ethanol injection -Resection -Combination 126 (68%) Pre-LT a-FP level (IU/L) median, range - > < (2-7936) 5 (3%) 25 (14%) 152 (83%)

Results: pre-LT imaging

Results: histopathological findings

RadiologyHistology O inside Milan O outside Milan O inside Milan O outside Milan

Discrepancy in selection criteria Classification according to Milan criteria Pathology Within Outside Radiologywithin 132/185 (71%)40/185(22%) outside4/185 (2%)9/185 (5%) Classification according to UCSF criteria Pathology Within Outside Radiologywithin 150/185 (81%)28/185(15%) outside2/185 (1%)5/185 (3%) 40/172 (23%) patients fell outside MC due to : number of HCC 10/40 size of HCC 20/40 both 10/40 28/178 (16%) patients fell outside UCSF criteria due to: number of HCC 19/28 size of HCC 5/28 both 4/28

Discrepancy between radiological and histological findings Number of nodules: 104/185 (56%) 78 underestimated - 60 pts -> 1-2 nodules - 18 pts -> 3-4 nodules 26 overestimated by 1-2 nodules -10 treated between imaging and LT Size of biggest nodule: 158/182 (87%) 93 underestimated - 44 pts -> difference ≥ 10 mm 65 overestimated - 25 pts -> difference ≥ 10mm

Results: HCC recurrence post-LT 29/185 (15.6%) developed HCC recurrence after a median of 37m post LT (4-157) 16 (55%) -> liver 13 (45%) -> metastatic disease involving lungs, bones or lymph nodes 20/29 died after a median of 48 m post-LT (7-157) Imaging Outside Milan criteria: 4/29 (14%) Outside UCSF criteria: 3/29 (10%) Histopathology Outside Milan criteria: 16/29 (55%) Outside UCSF criteria: 10/29 (35%)

Results: HCC recurrence post-LT 29/185 (15.6%) developed HCC recurrence after a median of 37m post LT (4-157) 16 (55%) -> liver 13 (45%) -> metastatic disease involving lungs, bones or lymph nodes 20/29 died after a median of 48 m post-LT (7-157) 16/29 (55%) outside Milan criteria according to explant 14/29 (48%) underestimated by imaging - size of biggest HCC (n=10) - n. of nodules and size of biggest (n=4) Vs 13/29 (45%) inside Milan criteria according to explant 3/29 (10%) had aFP >1000 IU/l -> vs 2/153 (1.3%) in non recurrence patients 13/29 (45%) had aFP >100 IU/l -> vs 17/153(11%) in non recurrence patients

Results: HCC recurrence post-LT 29/185 (15.6%) recurrence 20/29 (69 %) died aFP pre-LT ? aFP >1000 IU/l -> n=3/29 (10%) aFP > 100 IU/l -> n= 13/29 (45%) Versus aFP pre-LT in the non-recurrence ? aFP >1000 IU/l -> n=2/153 (1.3%) aFP >100 IU/l -> n= 17/153 (11%)

Results: discrepancy between radiology and histopathology in patients with HCC recurrence N. of nodules: 11/29 (38%) Size of biggest HCC: 22/ 29 (76%) Milan criteria : 14/29 (48%) - size of biggest HCC (n=10) - n. of nodules and size of biggest (n=4) UCSF criteria: 8/29 (28%) - size of biggest HCC or total size (n=3) - n. of nodules (n=2) - both size & number (n=3)

Log rank p<0.001 underestimated no discrepancy or overestimated Kaplan Meier curve for HCC recurrence according to Milan Criteria discrepancy

Results: predictors of HCC recurrence post- LT In Cox regression f actors significantly associated were: 1.aFP levels p=0.001, OR=4.1, 95% CI= Radiological size of biggest nodule p=0.001,OR=1.04, 95% CI= Number of nodules p=0.6 What about the number of nodules? Cut-off ?

Results: predictors of HCC recurrence post- LT In Cox regression f actors significantly associated were: 1.aFP levels p=0.001, OR=4.1, 95% CI= Radiological size of biggest nodule p=0.001,OR=1.04, 95% CI= Number of nodules p=0.6 What about the number of nodules? Cut-off ? aFP cut-off= 100 IU/l Sensitivity 41% Specificity 89% Cut-off of biggest nodule size = 3 cm Sensivity 62% Specificity 74%

Results: predictors of HCC recurrence post- LT aFP cut-off= 100 IU/l Sensitivity 41% Specificity 89% AUROC = p= % CI=0.6 – 0.8

Results: predictors of HCC recurrence post- LT Cut-off of biggest nodule diameter = 3 cm Sensivity 62% Specificity 74% AUROC =0.707 p=0.0001, 95% CI=0.6 – 0.8

…what if we combine aFP <100 IU/l and size of biggest nodule <3 cm ? AUROC=0.72, p=0.0001, 95% CI= Sensitivity=77% Specificity= 70%

We then compared our cut-offs with those proposed in the literature Total number of patientsRecurrence HCC aFP (IU/l) < (83%)16 (55%) (14%)10 (35%) >10005 (3%)3 (10%) Size of biggest nodule (cm) <3117 (76%)11 (38%) >336 (24%)18 (62%)

Kaplan Meier for HCC recurrence according to aFP and size of biggest HCC cut-offs aFP<100 and diam<3cm aFP>1000 and diam>3cm aFP 3cm aFP and diam<3cm aFP and diam>3cm Log rank p<0.001

Results: HCC recurrence post-LT 29/185 (15.6%) recurrence How many outside selection criteria on imaging? Outside Milan criteria: 4/29 (14%) Outside UCSF criteria: 3/29 (10%) Outside“aFP<100 IU/L + biggest nodule<3 cm”: 22/29 (76%)

Results: Survival post-LT 49/185 (27%) patients died after a mean of 42 months (6-160) post-LT HCC related 1-year survival 98%, 5-year survival 91% Overall related 1-year survival 95%, 5-year survival 80% Cause of death: HCC recurrence (41%) - median follow-up 40 months (7-157) - 1-year survival 89% - 5-year survival 53% de-novo malignancy (15%) decompensated cirrhosis (14%) sepsis (10%) chronic rejection (4%) Unknown, but not HCC-related (16%)

Results: predictors of HCC-related mortality post-LT Cox regression: pre-LT factors significantly associated: 1. aFP levels >100kU/l p<0.001, OR=5.1, 95% CI= Radiological size of biggest HCC p=0.021,OR=1.04, 95% CI=

aFP>1000 and diam>3cm aFP<100 and diam<3cm aFP 3cm aFP and diam<3cm aFP and diam>3cm Kaplan Meier for HCC-related survival according to aFP and size of biggest HCC cut-offs

Conclusions 1.Discordance between radiological and histological findings.  tumour progression between imaging and LT (tumour biology, waiting time)  innacurate imaging staging ? Does it really matter?  Recurrence occured in 35% of underestimated patients (vs 10% of the rest) according to Milan Criteria  4 (2%) overestimated according Milan criteria: how many patients we are overestimating and not listing ?

Conclusions 2. aFP and radiological diameter of the biggest HCC were the only pre-LT factors significantly associated with HCC recurrence and HCC related survival. A lower aFP cut-off of 100 IU/l showed higher sensitivity than the current in identifying HCC recurrence post LT Combination of aFP <100 Ku/l and size of biggest HCC <30 mm seems to perform better than the actual selection criteria. We do propose to consider patients with diameter>30mm for LT when aFP <100 IU/L.

Acknowledgements

Median TAC levels up to 30 days post LT was not associated with recurrence (p=0.6, OR=0.97, 95% CI )

aFP 400 IU/l Only 7 patients had aFP greater than 400 IU/l Cox regression: p=0.12, OR=2.4, 95% CI=

Underestimation over time In Milan criteria : 12/46 (26%) : 10/38 (26%) : 8/52 (15%) : 10/49 (20%) In number of nodules : 24/46 (52%) : 17/38 (45%) : 18/52 (34%) : 19/49 (38%) In size of biggest nodule : 29/46 (63%) : 21/38 (55%) : 25/52 (48%) : 18/49 (37%)